|
시장보고서
상품코드
2052542
비소세포폐암 시장 : 종류별, 치료법별, 최종사용자별, 지역별Non-Small Cell Lung Cancer Market, By Type, By Treatment, By End User, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
비소세포폐암 시장은 2026년에 314억 1,000만 달러로 추정되며, 2033년까지 604억 4,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 9.8%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 314억 1,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 9.80% | 2033년 시장 규모 예측: | 604억 4,000만 달러 |
비소세포폐암(NSCLC)은 폐암의 약 85%를 차지하는 가장 흔한 폐암 유형입니다. 이는 전 세계적으로 암으로 인한 사망의 주요 원인 중 하나입니다. 세계 비소세포폐암 시장의 성장은 흡연 습관 및 환경오염 증가, 첨단 치료법에 대한 연구개발 활동 증가, 표적 치료제 및 맞춤의료에 대한 수요 증가 등의 요인에 의해 주도되고 있습니다. 그러나 높은 치료비가 시장 성장을 가로막고 있습니다.
시장 역학
세계 비소세포폐암 시장의 성장은 선진국과 개발도상국의 흡연율 증가, 환경오염 수준 악화, 고령화 등에 의해 주도되고 있습니다. 세계보건기구(WHO)에 따르면, 전 세계적으로 매년 약 180만 건의 신규 폐암이 보고되고 있으며, 그 중 대부분이 비소세포폐암입니다. 표적 치료제와 암 치료법의 발전은 시장 관계자들에게 비즈니스 기회를 제공하고 있습니다. 그러나 표적 치료제에 따른 높은 비용과 저소득 국가에서의 낮은 인지도가 시장 성장을 저해하고 있습니다. 또한, 임상시험 중 약물 개발 실패의 위험도 연구개발 활동에 부정적인 영향을 미치고 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 비소세포폐암 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서는 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 세계 비소세포폐암 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 비소세포폐암 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 비소세포폐암 시장 : 유형별, 2021-2033년
제5장 세계의 비소세포폐암 시장 : 치료별, 2021-2033년
제6장 세계의 비소세포폐암 시장 : 최종사용자별, 2021-2033년
제7장 세계의 비소세포폐암 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 섹션
KSMNon-Small Cell Lung Cancer Market is estimated to be valued at USD 31.41 Bn in 2026 and is expected to reach USD 60.44 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 31.41 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 60.44 Bn |
Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.
Market Dynamics
Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.
Market Segmentation
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Large Cell Neuroendocrine Tumors
- Treatment Insights (Revenue, USD Bn, 2021 - 2033)
- Chemotherapy
- Targeted Therapy
- Bevacizumab (Avastin)
- Necitumumab (Portrazza)
- Ramucirumab (Cyramza)
- Immunotherapy
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- F. Hoffmann-La Roche Ltd.
- Honeywell International Inc.
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Non-Small Cell Lung Cancer Market, By Type, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adenocarcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Squamous Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Large Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Large Cell Neuroendocrine Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Non-Small Cell Lung Cancer Market, By Treatment, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Bevacizumab (Avastin)
- Necitumumab (Portrazza)
- Ramucirumab (Cyramza)
- Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Non-Small Cell Lung Cancer Market, By End User, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Home Care
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Non-Small Cell Lung Cancer Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Honeywell International Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca PLC
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Celgene Corporation
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. Section
- References
- Research Methodology
- About Us and Sales Contact
